| 國家衛生研究院 |
2005 |
Survival outcome of inoperable non-small cell lung cancer patients receiving conventional dose epirubicin and paclitaxel as first-line treatment
|
Yang, CH; Chen, MC; Cheng, AL; Hsu, CH; Yeh, KH; Yu, YC; Whang-Peng, J; Yang, PC |
| 國立臺灣大學 |
2005 |
Survival Outcome of Inoperable Non-Small Cell Lung Cancer Patients Receiving Conventional Dose Epirubicin and Paclitaxel as First-Line Treatment
|
楊志新; 陳明君; 鄭安理; 徐志宏; 葉坤輝; 汪彭嘉康; 楊泮池; YANG, CHIH-HSIN; CHEN, MIN-CHUN; CHENG, ANN-LII; HSU, CHIH-HUNG; YEH, KUN-HUEI; JACQUELINE, WHANG-PENG; YANG, PAN-CHYR |
| 臺大學術典藏 |
2020-04-28T07:25:36Z |
Survival outcome of inoperable non-small cell lung cancer patients receiving conventional dose epirubicin and paclitaxel as first-line treatment
|
Yang C.-H.; Chen M.-C.; Cheng A.-L.; CHIH-HUNG HSU; Yeh K.-H.; Yu Y.-C.; Whang-Peng J.; Yang P.-C.; Yang C.-H.;Chen M.-C.;Cheng A.-L.;Chih-Hung Hsu;Yeh K.-H.;Yu Y.-C.;Whang-Peng J.;Yang P.-C. |
| 臺大學術典藏 |
2020-05-26T09:27:28Z |
Survival outcome of inoperable non-small cell lung cancer patients receiving conventional dose epirubicin and paclitaxel as first-line treatment
|
Chih-Hsin Yang;Chen M.-C;Cheng A.-L;Hsu C.-H;Yeh K.-H;Yu Y.-C;Whang-Peng J;Yang P.-C.; CHIH-HSIN YANG; Chen M.-C; Cheng A.-L; Hsu C.-H; Yeh K.-H; Yu Y.-C; Whang-Peng J; Yang P.-C. |
| 臺大學術典藏 |
2020-12-02T02:35:41Z |
Survival outcome of inoperable non-small cell lung cancer patients receiving conventional dose epirubicin and paclitaxel as first-line treatment
|
PAN-CHYR YANG; Yang C.-H.;Chen M.-C.;Cheng A.-L.;Hsu C.-H.;Yeh K.-H.;Yu Y.-C.;Whang-Peng J.;Pan-Chyr Yang; Yang C.-H.; Chen M.-C.; Cheng A.-L.; Hsu C.-H.; Yeh K.-H.; Yu Y.-C.; Whang-Peng J. |
| 臺大學術典藏 |
2021-09-01T02:02:15Z |
Survival outcome of inoperable non-small cell lung cancer patients receiving conventional dose epirubicin and paclitaxel as first-line treatment
|
Yang C.-H.; Chen M.-C.; ANN-LII CHENG; Hsu C.-H.; Yeh K.-H.; Yu Y.-C.; Whang-Peng J.; Yang P.-C. |
| 臺大學術典藏 |
2021-01-28T01:06:48Z |
Survival outcome of inoperable non-small cell lung cancer patients receiving conventional dose epirubicin and paclitaxel as first-line treatment
|
Yang C.-H.;Chen M.-C.;Cheng A.-L.;Hsu C.-H.;Kun-Huei Yeh;Yu Y.-C.;Whang-Peng J.;Yang P.-C.; Yang C.-H.; Chen M.-C.; Cheng A.-L.; Hsu C.-H.; KUN-HUEI YEH; Yu Y.-C.; Whang-Peng J.; Yang P.-C. |
| 國立臺灣大學 |
2005-07 |
Survival outcome of inoperable non-small cell lung cancer patients receiving conventional dose epirubicin and paclitaxel as first-line treatment.
|
Yang, CH; Chen, MC; Cheng, AL; Hsu, CH; Kun-Huei, Yeh; Yu, YC; Whang-Peng, J; Yang, PC. |
| 中國醫藥大學 |
2015-08 |
Survival outcome of patients with nasopharyngeal carcinoma: a nationwide analysis of 13 407 patients in Taiwan.
|
(Huang, W.-Y.);林橙莉;(Lin, C.-Y.);(Jen, Y.-M.);(Lo, C.-H.);宋鴻樟(Fung-Chang Sung);高嘉鴻(Chia-Hung Kao)* |
| 國立成功大學 |
2022-03-8 |
Survival Outcome of Surgical Resection vs. Radiotherapy in Brain Metastasis From Colorectal Cancer: A Meta-Analysis
|
Chang;Yu;Wong;Chia-En;Lee;Po-Hsuan;Huang;Chi-Chen;Lee;Jung-Shun |
